Background: Severe clinical cases exclusively associated with Plasmodium vivax are increasingly being reported worldwide with complications like renal failure, jaundice, acute respiratory distress syndrome, cerebral malaria, seizures, anemia, thrombocytopenia, pulmonary edema, splenic rupture and death. Recently vivax severity has been on the rise in India where P.vivax contributes in equal ratio with P.falciparum to the disease. Two main transporters studied with regard to chloroquine resistance (CQR) are chloroquine resistance transporter (pvcrt-o) and the multidrug resistance transporter (pvmdr1) orthologous to the pfcrt and pfmdr1 genes respectively. Even though these transporters are not established as molecular markers for CQR, they have a speculated role in CQR of P.vivax. Further, it has been demonstrated that the clinical severity in P.vivax could be associated with increased expression levels of pvcrt-o and pvmdr1 genes.
Background: Mistrust, suspicion and rumours have circulated around the purpose and motives behind recent Ebola vaccine clinical trials. EBOVAC-Salone is a community-based Phase II trial of the candidate Ad26.ZEBOV/MVA-BN-Filo prime-boost vaccine regimen against Ebola being conducted in Kambia, Sierra Leone. In this setting, we established a system for regular dialogue between trial staff and community members in order to build and sustain trust and to provide a mechanism to listen and respond promptly to rumours, concerns or misinformation in the community.
Methods & Materials: A local community liaison team engage with the community at levels. Strategies include one-toone engagement with key stakeholders; public meetings with influential civil society and traditional leaders; house-to-house sensitisation, and use of traditional communication media such as radio.
In addition, a social science team act as the 'eyes and ears' for the trial, listening to what individuals are saying about the study through both informal community observation and formal clinic exit interviews, in-depth interviews with participants and key stakeholders, and focus group discussions. The social science team provide daily feedback to the community liaison team on any rumours, concerns or misinformation circulating in the community, to inform prompt responses or clarifications. Furthermore, an external communications manager monitors national-level rumours and concerns and provides information on the trial at national and international level.
Results: Full engagement has occurred with both local leaders and the community. Enrolment in the trial has occurred successfully thus far, with trial participants voluntarily acting as ambassadors and encouraging others to volunteer. No disruption has occurred to the trial through rumours or misinformation thus far. Influential individuals in the community have assisted with disseminating messages and promptly addressing misconceptions.
Conclusion: Through a novel collaboration, we have formed an effective rapid response system for rumours and misinformation related to an Ebola vaccine trial during an outbreak. In addition, we have developed strong collaboration with the community through regular dialogue with stakeholders and trial participants. As a result, a community in rural Sierra Leone with no previous experience of medical research have developed a strong acceptance and understanding of the purpose of and processes involved in an Ebola vaccine trial. http://dx.doi.org/10.1016/j.ijid.2016.02.444
